REFERENCES The Papanicolaou test for cervical cancer detection: a triumph and a tragedy.

REFERENCES
1. Koss LG. The Papanicolaou test for cervical cancer detection: a triumph
and a tragedy. JAMA 1989;261:737–743.
2. Tabár L, Vitak B, Chen HH, et al. Beyond randomized controlled trials:
organized mammographic screening substantially reduces breast
carcinoma mortality. Cancer 2001;91:1724–1731.
3. Bach PB, Silvestri GA, Hanger M, et al. Screening for lung cancer.
ACCP evidence-based clinical practice guidelines. (2nd edition). Chest
2007;132(3 Suppl);S69–S77.
4. Shaipanich T, McWilliams A, Lam S. Early detection and chemoprevention
of lung cancer. Respirology 2006;11:366–372.
5. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer
risk among smokers. J Natl Cancer Inst 2003;95:470–478.
6. Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of
lung cancer. J Natl Cancer Inst 2007;99:715–726.
7. Hirsch FR, Prindiville SA, Miller YA, et al. Fluorescence versus whitelight
bronchoscopy for detection of preneoplastic lesions: a randomized
study. J Natl Cancer Inst 2001;93:1385–1391.
8. Haussinger K, Becker H, Stanzel F, et al. Autofluorescence bronchoscopy
with white light bronchoscopy compared with white light bronchoscopy
alone for the detection of precancerous lesions: a European
randomized controlled multicentre trial. Thorax 2005;60(6):496–503.
9. Kennedy TC, McWilliams A, Edell E, et al. Bronchial intraepithelial
neoplasia/early central airways lung cancer. ACCP evidence-based clinical
practice guidelines (2nd edition). Chest 2007;132:S221–S233.
10. Loewen G, Natarajan N, Tan D, et al. Autofluorescence bronchoscopy
for lung cancer surveillance based on risk assessment. Thorax
2007;62:335–340.
11. Chhajed PN, Shibuya K, Hoshino H, et al. A comparison of video and
autofluorescence bronchoscopy in patients at high risk of lung cancer.
Eur Respir J 2005;25:951–955.
12. Hanna N, Saltzman D, Mukai D, et al. Two-dimensional and
3-dimensional optical coherence tomographic imaging of the airway,
lung, and pleura. J Thorac Cardiovasc Surg 2005;129:615–622.
13. Shulman L, Ost D. Advances in bronchoscopic diagnosis of lung cancer.
Curr Opin Pulm Med 2007;13:271–277.
14. Kim YL, Turzhitsky VM, Liu Y, et al. Low-coherence enhanced backscattering:
review of principles and applications for colon cancer screening.
J Biomed Opt 2006;11:041125.
15. Horton KM, Horton MR, Fishman EK. Advanced visualization of airways
with 64-MDCT: 3D mapping and virtual bronchoscopy. AJR Am
J Roentgenol 2007;189:1387–1396.
16. Weir BA. Woo MS, Getz G, et al. Characterizing the cancer genome in
lung adenocarcinoma. Nature 2007;450(7171):893–898.
17. Jones PA, Takai D. The role of DNA methylation in mammalian genetics.
Science 2001;293:1068–1070.
18. Baylin SB, Schuebel KE. Genomic biology: the epigenomic era opens.
Nature 2007;448:548–549.
19. Bird A. Perceptions of epigenetics. Nature 2007;447:396–398.
20. Shames DS, Girard L, Gao B, et al. A genome-wide screen for promoter
methylation in lung cancer identifies novel methylation markers
for multiple malignancies. PLoS Med 2006;3:E486.
21. Rauch TA, Zhong X, Wu X, et al. High-resolution mapping of DNA
hypermethylation and hypomethylation in lung cancer. Proc Natl Acad
Sci U S A 2008;105:252–257.
22. Tsou JA, Galler JS, Siegmund KD, et al. Identification of a panel of
sensitive and specific DNA methylation markers for lung adenocarcinoma.
Mol Cancer 2007;6:70.
23. Kagan J, Srivastava S, Barker PE, et al. Towards clinical application of
methylated DNA sequences as cancer biomarkers: a joint NCI’s EDRN
and NIST workshop on standards, methods, assays, reagents, and tools.
Cancer Res 2007;67:4545–4549.
24. Sozzi G, Conte D, Leon M, et al. Quantification of free circulating DNA
as a diagnostic marker in lung cancer. J Clin Oncol 2003;21:3902–3908.
25. Herrera LJ, Raja S, Gooding WE, et al. Quantitative analysis of circulating
plasma DNA as a tumor marker in thoracic malignancies. Clin
Chem 2005;51:113–118.
26. Pathak AK, Bhutani M, Kumar S, et al. Circulating cell-free DNA in
plasma/serum of lung cancer patients as a potential screening and prognostic
tool. Clin Chem 2006;52:1833–1842.
27. Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA
and RNA markers in blood: a tool for early detection, diagnostics, and
follow-up? Lung Cancer 2005;49:1–12.
28. Peluso M, Munnia A, Hoek G, et al. DNA adducts and lung cancer
risk: a prospective study. Cancer Res 2005;65:8042–8048.
29. Godschalk RW, Van Schooten FJ, Bartsch H. A critical evaluation of
DNA adducts as biological markers for human exposure to polycyclic
aromatic compounds. J Biochem Mol Biol 2003;36:1–11.
30. Veglia F, Loft S, Matullo G, et al. DNA adducts and cancer risk in prospective
studies: a pooled analysis and a meta-analysis. Carcinogenesis
2008;29(5):932–936.
31. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of
aberrant promoter methylation of tumor suppressor genes in
serum DNA from non-small cell lung cancer patients. Cancer Res
1999;59:67–80.
32. Belinsky SA, Grimes MJ, Casas E, et al. Predicting gene promoter
methylation in non-small-cell lung cancer by evaluating sputum and
serum. Br J Cancer 2007;96:1278–1283.
33. Shivapurkar N, Stastny V, Suzuki M, et al. Application of a methylation
gene panel by quantitative PCR for lung cancers. Cancer Lett
2007;247:56–71.
34. Bailey-Wilson JE, Amos CI, Pinney SM, et al. A major lung cancer
susceptibility locus maps to chromosome 6q23–25. Am J Hum Genet
2004;75:460–474.
35. Nair U, Bartsch H. Metabolic polymorphisms as susceptibility markers
for lung and oral cavity cancer. IARC Sci Publ 2001;154:271–290.
36. Spitz MR, Wei Q, Dong Q, et al. Genetic susceptibility to lung cancer:
the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev
2003;12:689–698.
37. Wu X, Lin J, Etzel CJ, et al. Interplay between mutagen sensitivity and
epidemiological factors in modulating lung cancer risk. Int J Cancer
2007;120:2687–2695.
38. Hung RJ, Baragatti M, Thomas D, et al. Inherited predisposition
of lung cancer: a hierarchical modeling approach to DNA repair
and cell cycle control pathways. Cancer Epidemiol Biomarkers Prev
2007;16:2736–2744.
39. Engels EA, Wu X, Gu J, et al. Systematic evaluation of genetic variants
in the inflammation pathway and risk of lung cancer. Cancer Res
2007;67:6520–6527.
40. Xi L, Nicatri DG, El-Hefnawy T, et al. Optimal markers for real-time
quantitative reverse transcription PCR detection of circulating tumor
cells from melanoma, breast, colon, esophageal, head and neck, and
lung cancers. Clin Chem 2007;53:1206–1215.
41. Dom B, Timar J, Dobos J, et al. Identification and clinical significance
of circulating endothelial progenitor cells in human non-small cell lung
cancer. Cancer Res 2006;66:7341–7347.
42. Ge M-J, Shi D, Wu QC, et al. Observation of circulating tumour cells
in patients with non-small cell lung cancer by real-time fluorescent
quantitative reverse transcriptase-polymerase chain reaction in peroperative
period. J Cancer Res Clin Oncol 2006;132:248–256.
43. Vogel U, Nexø BA, Tjønneland A, et al. ERCC1, XPD and RAI
mRNA levels in lymphocytes are not associated with lung cancer risk
in a prospective study of Danes. Mutat Res 2006;593:88–96.
44. Massion PP, Caprioli RM. Proteomic strategies for the characterization and
the early detection of lung cancer. J Thorac Oncol 2006;1:1027–1039.
45. Yildiz PB, Shyr Y, Rahman JS, et al. Diagnostic accuracy of MALDI
mass spectrometric analysis of unfractionated serum in lung cancer.
J Thorac Oncol 2007;2:893–901.
46. Patz EF Jr, Campa MJ, Gottlin EB, et al. Panel of serum biomarkers for
the diagnosis of lung cancer. J Clin Oncol 2007;25:5578–5583.
47. Ishikawa N, Takano A, Yasui W, et al. Cancer-testis antigen lymphocyte
antigen 6 complex locus K is a serologic biomarker and a therapeutic
target for lung and esophageal carcinomas. Cancer Res 2007;67:
11601–11611.
48. Qiu J, Madoz-Gurpide J, Misek DE, et al. Development of natural
protein microarrays for diagnosing cancer based on an antibody response
to tumor antigens. J Proteome Res 2004;3:261–267.
49. Chapman CJ, Murray A, McElveen JE, et al. Autoantibodies in lung
cancer—possibilities for early detection and subsequent cure. Thorax
2008;63:228–233.
50. Coen M, Holmes E, Lindon JC, et al. NMR-based metabolic profiling
and metabonomic approaches to problems in molecular toxicology.
Chem Res Toxicol 2008;21:9–27.
51. Nordstrom A, Want E, Northen T, et al. Multiple ionization mass spectrometry
strategy used to reveal the complexity of metabolomics. Anal
Chem 2008;80:421–429.
52. Chen H, Pan Z, Talaty N, et al. Combining desorption electrospray
ionization mass spectrometry and nuclear magnetic resonance for differential
metabolomics without sample preparation. Rapid Commun
Mass Spectrom 2006;20:1577–1584.
53. Greenberg AK, Rimal B, Felner K, et al. S-adenosylmethionine as
a biomarker for the early detection of lung cancer. Chest 2007;132:
1247–1252.
54. Xing J, Spitz MR, Lu C, et al. Deficient G2-M and S checkpoints
are associated with increased lung cancer risk: a case-control analysis.
Cancer Epidemiol Biomarkers Prev 2007;16:1517–1522.
55. Wang W, Spitz MR, Yang H, et al. Genetic variants in cell cycle control
pathway confer susceptibility to lung cancer. Clin Cancer Res
2007;13:5974–5981.
56. Chorostowska-Wynimko J, Szpechcinski A. The impact of genetic
markers on the diagnosis of lung cancer: a current perspective. J Thorac
Oncol 2007;2:1044–1051.
57. Ortiz-de-Solorzano C, Ucar-Vargas B, Pengo T, et al. Computer assisted
detection of cancer cells in minimal samples of lung cancer. Conf
Proc IEEE Eng Med Biol Soc 2007;2007:5517–5520.
58. Spira A, Beane J, Shah V, et al. Effects of cigarette smoke on the
human airway epithelial cell transcriptome. Proc Natl Acad Sci U S A
2004;101:10143–10148.
59. Spira A, Beane JE, Shah V, et al. Airway epithelial gene expression in
the diagnostic evaluation of smokers with suspect lung cancer. Nat Med
2007;13:361–366.
60. Sridhar S, Schembri F, Zeskind J, et al. Smoking-induced gene expression
changes in the bronchial airway are reflected in nasal and buccal
epithelium. BMC Genomics 2008;9:259.
61. Palcic B, Garner DM, Beveridge J, et al. Increase of sensitivity of sputum
cytology using high-resolution image cytometry: field study results.
Cytometry 2002;50:168–176.
62. Keohavong P, Gao WM, Zheng KC, et al. Detection of K-ras and p53
mutations in sputum samples of lung cancer patients using laser capture
microdissection microscope and mutation analysis. Anal Biochem
2004;324:92–99.
63. Keohavong P, Lan Q, Gao WM, et al. Detection of p53 and K-ras
mutations in sputum of individuals exposed to smoky coal emissions in
Xuan Wei County, China. Carcinogenesis 2005;26:303–308.
64. Li R, Todd NW, Qiu Q, et al. Genetic deletions in sputum as diagnostic
markers for early detection of stage I non-small cell lung cancer.
Clin Cancer Res 2007;13:482–487.
65. Castagnaro A, Marangio E, Verduri A, et al. Microsatellite analysis of
induced sputum DNA in patients with lung cancer, in heavy smokers,
and in healthy subjects. Exp Lung Res 2007;33:289–301.
66. Belinsky SA. Gene promoter hypermethylation as a biomarker in lung
cancer. Nat Rev Cancer 2004;4:707–717.
67. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation
of multiple genes in sputum precedes lung cancer incidence in a
high-risk cohort. Cancer Res 2006;66:3338–3344.
68. Lacroix J, Becker HD, Woerner SM, et al. Sensitive detection of
rare cancer cells in sputum and peripheral blood samples of patients
with lung cancer by preproGRP-specific RT-PCR. Int J Cancer 2001;
92:1–8.
69. Jheon S, Hyun DS, Lee SC, et al. Lung cancer detection by a RTnested
PCR using MAGE A1—6 common primers. Lung Cancer
2004;43:29–37.
70. Sueoka E, Sueoka N, Goto Y, et al. Heterogeneous nuclear ribonucleoprotein
B1 as early cancer biomarker for occult cancer of human lungs
and bronchial dysplasia. Cancer Res 2001;61:1896–1902.
71. Pasrija T, Srinivasan R, Behera D, et al. Telomerase activity in sputum
and telomerase and its components in biopsies of advanced lung cancer.
Eur J Cancer 2007;43:1476–1482.
72. Wehinger A, Schmid A, Mechtcheriakov S, et al. Lung cancer detection
by proton transfer reaction mass-spectrometric analysis of human
breath gas. Int J Mass Spectrometry 2007;265:49–59.
73. Phillips M, Gleeson K, Hughes JM, et al. Volatile organic compounds
in breath as markers of lung cancer: a cross-sectional study. Lancet
1999;353:1930–1933.
74. Phillips M, Cataneo RN, Cummin ARC, et al. Detection of
lung cancer with volatile markers in the breath. Chest 2003;123:
2115–2123.
75. Phillips M, Altorki N, Austin JH, et al. Prediction of lung cancer using
volatile biomarkers in breath. Cancer Biomark 2007;3(2):95–109.
76. Machado R, Laskowski D, Deffenderfer O, et al. Detection of lung
cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care
Med 2005;171:1286–1291.
77. Mazzone PJ, Hammel J, Dweik R, et al. Diagnosis of lung cancer by
the analysis of exhaled breath with a colorimetric sensor assay. Thorax
2007;62:565–568.
78. McCulloch M, Jezierski T, Broffman M, et al. Diagnostic accuracy of
canine scent detection in early- and late-stage lung and breast cancers.
Integr Cancer Ther 2006;5:30–39.
79. Chen X, Xu F, Wang Y, et al. A study of the volatile organic compounds
exhaled by lung cancer cells in vitro for breath diagnosis. Cancer
2007;110:835–844.
80. Carpagnano GE, Spanevello A, Curci C, et al. IL-2, TNF-alpha, and
leptin: local versus systemic concentrations in NSCLC patients. Oncol
Res 2007;16:375–381.
81. Gessner C, Kuhn H, Toepfer K, et al. Detection of p53 mutations in
exhaled breath condensate of non-small cell lung cancer patients. Lung
Cancer 2004;43:215–222.
82. Carpagnano GE, Foschino-Barbaro MP, Mulé G, et al. 3p microsatellite
alterations in exhaled breath condensate from patients with nonsmall
cell lung cancer. Am J Respir Crit Care Med 2005;172:738–744.
83. Carpagnano GE, Foschino-Barbaro MP, et al. 3p microsatellite signature
in exhaled breath condensate and tumor tissue of patients with
lung cancer. Am J Respir Crit Care Med 2008;77:246–247.
84. Han W, Cauchi S, Herman JG, et al. Methylation mapping of DNA
by tag-modified bisulfite genomic DNA sequencing. Anal Biochem
2006;355:50–61.
85. Han W, Wang T, Reilly AA, et al. Gene promoter methylation assayed
in exhaled breath, with differences in smokers and lung cancer patients.
Respir Res 2009;10:86.
86. Spivack SD, Hurteau GJ, Jain R, et al. Gene-environment interaction
signatures by quantitative mRNA profiling in exfoliated buccal mucosal
cells. Cancer Res 2004;64:6805–6813.